This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A <u>purified</u> compound of formula 1:

Formula 1

and pharmaceutically acceptable salts, prodrugs, tautomers, and solvates, thereof.

2. (Currently amended) A <u>purified</u> compound having the formula 2:

. Formula 2

and pharmaceutically acceptable salts, prodrugs, tautomers, and solvates, thereof.

- 3. (Currently amended) A pharmaceutical composition comprising a <u>purified</u> compound <u>according to either one of as defined in claims 1 or 2 and a pharmaceutically acceptable carrier, vehicle or diluent.</u>
- 4. (Currently amended) A method of treating any <u>a</u> mammal, preferably a human, affected by cancer or psoriasis which comprises comprising:

administering to the affected individual mammal a therapeutically effective amount of a compound according to either one of as defined in claims 1 or 2.

5. (Currently amended) [[A]] <u>The</u> method according to claim 4 wherein the mammal is a human and he is affected by cancer.

- 6. (Currently amended) [[A]] <u>The</u> method according to claim 5 wherein the patient has a cancer is a refractory cancer that does not respond favourably to other treatments.
- 7. (Currently amended) The method [[of]] according to claim 5 wherein the cancer is selected from prostate cancer, breast cancer, hepatocellular carcinoma, melanoma, colorectal cancer, renal cancer, ovarian cancer, NSCL cancer, epithelial cancer, pancreatic cancer and tumors that overexpress the Her2/neu oncogene.
- 8. (Currently amended) A method of manufacturing The use of a compound as defined in elaim 1 or 2 in the manufacture of a medicament comprising:

combining a compound according to either one of claims 1 or 2 with a pharmaceutically acceptable carrier, vehicle or diluent.

- 9. (Currently amended) The method of manufacturing a medicament according to claim 8,

 The use of compound as defined in claim 1-or 2 in the manufacture of a wherein the medicament

 is a for the treatment [[of]] for cancer, psoriasis, viral infection or fungal infection.
- 10. (Currently amended) A kit comprising separate containers containing a pharmaceutical composition comprising a compound as defined in according to either one of claims 1 or 2 and a reconstituting agent.
- 11. (Currently amended) A <u>method of process for the preparation of preparing</u> a compound as defined in according to either one of claims 1 or 2 <u>comprising</u>:

<u>Converting 4-MeHex-D-Val-Thr(tBu)-Val-D-Val-D-Pro-Orn(Boc)-D-allo-Ile-D-allo-Ile-D-allo-Ile-D-Val-D-Pro-Orn-D-allo-Ile-D-Val-D-Val-D-Val-D-Val-D-Val-D-Pro-Orn-D-allo-Ile-cyclo(D-allo-Thr-D-allo-Ile-D-Val-Phe-Z-Dhb-Val).</u>

12. (Currently amended) A method for preparing a compound according to process according to claim 1 comprising:

<u>providing 11 characterized in that it uses</u> 4- methyl hexanoic acid as <u>a</u> starting material <u>in</u> a process for preparing the compound according to claim 1.

13. (Currently amended) A method for preparing a compound according to process according to claim 2 comprising:

providing 11 characterized in that it uses (4S)- methyl hexanoic acid as a starting material in a process for preparing the compound according to claim 2.

14. (New) A method of treating a human with cancer comprising:

administering a therapeutically effective amount of a compound according to claim 2 to a human with a type of cancer for which the compound according to claim 2 is more efficacious than 5-methyl hexanoic kahalalide F.

15. (New) The method of claim 14 wherein the cancer is selected from hepatocellular carcinoma, human liver adenocarcinoma, breast cancer, and prostate cancer.